Allspring Global Investments
KLRS

Allspring Global Investments’s Kalaris Therapeutics KLRS Stock Holding History

Allspring Global Investments’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-142
Closed -$11.1K – 2911
2023
Q2 		$11.1K Buy
142
+116
+446% +$11K ﹤0.01% 2529
2023
Q1 		$2.31K Buy
+26
New +$3.31K ﹤0.01% 2705

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allspring Global Investments's KLRS Position: Q3 2023 in Review

Allspring Global Investments sold out of Kalaris Therapeutics (KLRS) in Q3 2023, closing a stake of 142 shares — an estimated $11.1K sold.

Allspring Global Investments first reported a position in KLRS in Q1 2023 and held it in 2 quarters. The position peaked at $11.1K in Q2 2023. 90 funds tracked by Wall St. Rank hold KLRS as of Q3 2023.

  • Allspring Global Investments reported no remaining Kalaris Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Allspring Global Investments sold 142 Kalaris Therapeutics shares in Q3 2023, an estimated $11.1K.
  • Allspring Global Investments first reported a position in Kalaris Therapeutics in Q1 2023 and held it in 2 quarters.
  • Allspring Global Investments's Kalaris Therapeutics position peaked at $11.1K in Q2 2023.
  • 90 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2023.

Based on Allspring Global Investments's 13F filing for Q3 2023, filed 27 Oct 2023.